Mass spectrometer for Alderley Analytical

Above: Gavin Cowling of FW Capital which provided the funding (second from right) with (L-R) Alderley Analytical’s Claire Ayre, Sally Hannam, Paul Holme and Liz Thomas

Biomedical research company Alderley Analytical has received £300k funding from the Northern Powerhouse Investment Fund.

The Macclesfield-based company, which currently employs 21 people, is expecting to create at least six jobs in the coming months.

The firm has grown its turnover from £33k in 2014 to over £1m last year, with forecasts pointing to turnover growth of more than 60% this year.

Alderley Analytical is a bioanalytical contract research business, supporting the development of new drugs by measuring their levels in biological fluid samples.

It was among the first companies to move into the new Alderley Park Science Park at the former AstraZeneca R&D campus in Cheshire. The company was founded in 2014 by Elizabeth Thomas, Paul Holme, Sally Hannam and Claire Wildgoose.

Chief exec Elizabeth Thomas said: “The funding has been used to recruit new staff and buy a new Mass Spectrometer, a high-tech piece of equipment which is used to measure drug levels in biological fluids.

“The data we generate leads to the right dose getting to the right patient and ultimately helps to get new medicines to market.”